Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ancilla Domini D-2 inverse transcription therapeutics for type 2 diabetes
PACTR202409885980073Phase 1Not yet recruiting
- Sponsor
- Ancilla Domini International Researchers
- Start
- Nov 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in type 2 diabetes mellitus (T2DM), sponsored by Ancilla Domini International Researchers. Planned start Nov 2024; status: not yet recruiting.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on PACTR202409885980073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202409885980073.